Avalon GloboCare Forms Joint Venture With Jiangsu Unicorn to Establish Provincial Network of Translational Cellular Therapy & Bio-Banking Programs


Avalon GloboCare Corp. recently announced it has formed a joint venture with Jiangsu Unicorn Biological Technology Co. Ltd, which brings extensive medical resources in Jiangsu Province, China.

This partnership was established to lead to the development of a premium network of provincial centers of excellence for translational research, collaborating in the areas of technological, clinical, and regulatory resources in the areas of cellular therapy and bio-banking from top-ranked hospitals, including Nanjing Drum Tower Hospital, Nanjing Hospital of Chinese Medicine, Nanjing BenQ Hospital and the Second Affiliated Hospital of Nanjing Medical University.

One of the major initiatives of this partnership is to establish the world’s largest aqueous humor-derived exosome bio-bank to advance the next-generation of diagnosis and therapeutics for ophthalmologic diseases. This joint venture also aims to enhance the translational research and development of standardization, validation, processing, bio-production, international collaboration, and high-impact clinical studies with respect to cellular therapy (including stem cell and CAR-T) in Jiangsu Province, China.

“This partnership with Jiangsu Unicorn provides an exceptional opportunity for Avalon to effectively leverage our technical and clinical expertise to expand our programs in exosome technology, cellular therapeutics and bio-banking,” stated David Jin, MD, PhD, CEO and President of Avalon GloboCare Corp. “Through this provincial network of translational programs, we are able to further strengthen our leadership role and capabilities in order to accelerate our growth and development in regenerative medicine and cellular therapies.”

 Avalon GloboCare Corp. is a global intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high impact, transformative cell-based /technologies and their clinical applications, as well as healthcare facility management through its core platforms, namely Avalon Cell and Avalon Rehab. In addition, Avalon provides strategic advisory and outsourcing services to facilitate and enhance their clients’ growth, development, as well as competitiveness in both domestic and global healthcare markets. Avalon also engages in the management of stem cell banks and specialty clinical laboratories. Through its US subsidiary, GenExosome Technologies Inc., Avalon further establishes its leading role in the fields of liquid biopsy, precision medicine and regenerative medicine.